ATE296668T1 - Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam- 1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren,enthalten - Google Patents

Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam- 1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren,enthalten

Info

Publication number
ATE296668T1
ATE296668T1 AT00961433T AT00961433T ATE296668T1 AT E296668 T1 ATE296668 T1 AT E296668T1 AT 00961433 T AT00961433 T AT 00961433T AT 00961433 T AT00961433 T AT 00961433T AT E296668 T1 ATE296668 T1 AT E296668T1
Authority
AT
Austria
Prior art keywords
inhibit
agents
interactions
lfa
compositions
Prior art date
Application number
AT00961433T
Other languages
English (en)
Inventor
Donald J Souza
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE296668T1 publication Critical patent/ATE296668T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00961433T 1999-09-01 2000-08-31 Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam- 1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren,enthalten ATE296668T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15195399P 1999-09-01 1999-09-01
US15216899P 1999-09-02 1999-09-02
US16485499P 1999-11-12 1999-11-12
PCT/US2000/023873 WO2001015733A2 (en) 1999-09-01 2000-08-31 Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction

Publications (1)

Publication Number Publication Date
ATE296668T1 true ATE296668T1 (de) 2005-06-15

Family

ID=27387194

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961433T ATE296668T1 (de) 1999-09-01 2000-08-31 Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam- 1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren,enthalten

Country Status (9)

Country Link
EP (1) EP1218064B1 (de)
JP (1) JP2003508448A (de)
AT (1) ATE296668T1 (de)
AU (1) AU7338500A (de)
CA (1) CA2383773A1 (de)
DE (1) DE60020580T2 (de)
ES (1) ES2243301T3 (de)
MX (1) MXPA02002136A (de)
WO (1) WO2001015733A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP3845735B2 (ja) * 2002-04-03 2006-11-15 学校法人慶應義塾 Ｃｄ４０ｌアンタゴニストを有効成分とする天疱瘡治療剤
JP4617449B2 (ja) 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
MX2012002766A (es) * 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2976381B2 (ja) * 1988-09-28 1999-11-10 ダナ ファーバー キャンサー インスティテュート 細胞間粘着分子およびその結合性リガンド

Also Published As

Publication number Publication date
EP1218064A2 (de) 2002-07-03
AU7338500A (en) 2001-03-26
WO2001015733A3 (en) 2001-09-13
MXPA02002136A (es) 2002-09-18
WO2001015733A2 (en) 2001-03-08
DE60020580D1 (de) 2005-07-07
ES2243301T3 (es) 2005-12-01
EP1218064B1 (de) 2005-06-01
DE60020580T2 (de) 2006-04-27
CA2383773A1 (en) 2001-03-08
JP2003508448A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
ATE328588T1 (de) Behandlung von nicotinsucht und sucht bedingtem verhalten
BR0110420A (pt) Agonistas muscarìnicos
ATE328599T1 (de) Antitumorale mittel
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
DE69521700T2 (de) Mittel und methoden zur behandlung von plaque-krankheiten
PT902789E (pt) Derivados de androsteno
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
Barrett et al. Adrenergic neuron blocking properties of (±)‐propranolol and (+)‐propranolol
Marchand et al. Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat
DE69835824D1 (de) Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
Thomander et al. Motor fibre organization in the intratemporal portion of cat and rat facial nerve studied with the horseradish peroxidase technique
ATE296668T1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam- 1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren,enthalten
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE69705110D1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
ATE238803T1 (de) Pphospholipidkomplexe von proanthocyanidin a2 als antiatherosklerotische mittel
EA200400348A1 (ru) Цисплатиновые составы пониженной токсичности и способы их применения
EP1663280A4 (de) Verfahren zur verbesserung der hämatopoiese
ATE210368T1 (de) Mittel zur behandlung von vogelstreu
ATE232739T1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE69918826D1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
DE60318467D1 (de) Pomolsäure zur behandlung von mehrfachresistenten tumoren
DE60210268D1 (de) Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties